Latest Breaking News On - Novo nordisk foundation - Page 8 : vimarsana.com

GLP1 Receptor Agonist Use Does Not Seem to Increase Risk for Thyroid Cancer

No increased risk for thyroid cancer seen with use of GLP1 receptor agonist versus DPP4 inhibitor use, SGLT2 inhibitor use. No increased risk for thyroid cancer seen with use of GLP1 receptor agonist versus DPP4 inhibitor use, SGLT2 inhibitor use.

Novo Holdings to invest €188m in quantum computing

Denmark’s Novo Holdings is to invest DKK1.4bn (€188m) in quantum computing research.

🔒 How Ozempic became the epicentre of the Danish economy

In the wake of Ozempic and Wegovy's global dominance, Novo Nordisk emerges as a transformative force in Denmark's socio-economic fabric.

Enzymes open new path to universal donor blood

Scientific leaders gather at global summit in Denmark to advance knowledge and solutions on health and sustainability

Specific class of drugs can reverse diet-induced obesity, fatty liver and diabetes in mice

Researchers at Karolinska Institutet may have found a new way to treat obesity and related disorders by targeting the cells' powerhouses, the mitochondria.

Enzymes open new path to universal donor blood

Researchers at DTU and Lund University have discovered enzymes that remove hindrances that stood in the way of developing universal donor blood.

Ozempic Maker Novo Nordisk Has Denmark's Economy Hooked

Enzyme discovery paves the way for developing universal donor blood

Researchers at DTU and Lund University have discovered enzymes that remove hindrances that stood in the way of developing universal donor blood.

GLP1 Receptor Agonist Use Does Not Seem to Increase Risk for Thyroid Cancer

WEDNESDAY, April 24, 2024 (HealthDay News) -- Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid cancer, according to a study published online April 10 in The BMJ. Björn Pasternak, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues examined whether use of a